NCT06260774 - Study of TTX-MC138 in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 5, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

February 1, 2027

Conditions

Advanced Solid Tumor

Interventions

DRUG

TTX-MC138

The starting dose of TTX-MC138 in the first cohort will be 0.4 mg/kg and will be increased incrementally in subsequent cohorts until maximum tolerated dose (MTD) determination.

Trial Locations (4)

22031

Next Oncology, Fairfax

75230

Mary Crowley Cancer Center, Dallas

77230

MD Anderson Cancer Center, Houston

84119

START Mountain Region, West Valley City